Evaluation of Effect of Neoadjuvant Therapy Using Positron Emission Tomography

2017 ◽  
pp. 45-58
Author(s):  
Ik Jae Lee ◽  
Jinsil Seong
Keyword(s):  
Positron Emission Tomography ◽  
Neoadjuvant Therapy ◽  
Emission Tomography ◽  
Positron Emission

Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15766-e15766
Author(s):  
Chad Barnes ◽  
Mohammed Aldakkak ◽  
Kathleen K. Christians ◽  
Parag Tolat ◽  
Paul S. Ritch ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Neoadjuvant Therapy ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Prospective Trial ◽  
Standardized Uptake Value ◽  
Carbohydrate Antigen ◽  
Emission Tomography ◽  
Positron Emission

e15766 Background: The role of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging of pancreatic cancer (PC) has not been well defined. We evaluated the prognostic value of FDG-PET imaging in patients with localized PC enrolled in a prospective trial of personalized molecular-directed neoadjuvant therapy. Methods: Pretreatment FDG-PET was classified as high or low based on a standardized uptake value (SUV) cutpoint of 7.2 (population median). Carbohydrate antigen 19-9 (CA19-9) was measured after the completion of neoadjuvant therapy (preoperative) and classified as normal (≤35 U/mL) or elevated. Results: Pretreatment FDG-PET imaging was performed on 100 consecutive patients; SUV was high in 50 and low in 50. Preoperative CA19-9 values were available in 99 of 100 patients; 54 (55%) were elevated and 45 (45%) were normal. Of the 100 patients, 81 completed neoadjuvant therapy and surgery, and 19 were not resected. Among the 81 resected patients, SUV was high in 37 (46%) and low in 44 (54%); preoperative CA19-9 was elevated in 40 (49%) and normal in 41 (51%). The median overall survival (OS) for all patients was 39 months; 45 months for who completed all intended neoadjuvant therapy and surgery and 9 months for patients who were not resected. The median OS for patients with normal CA19-9/low SUV, normal CA19-9/high SUV, elevated CA19-9/low SUV, and elevated CA19-9/high SUV were not reached, 35, 24, and 18 months, respectively (p = 0.0001). Conclusions: Pretreatment FDG-PET avidity and preoperative CA19-9 are important prognostic markers and may be used to estimate the anticipated benefit of surgery; information of immediate clinical significance for both treatment sequencing and the application of surgery to patients who are frequently of advanced age or high-risk.

Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10512-10512 ◽  
Author(s):  
Jesus Garcia-Foncillas ◽  
Purificación Martinez ◽  
Ainhara Lahuerta ◽  
Antonio Llombart Cussac ◽  
Maria Garcia Gonzalez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Positron Emission Tomography ◽  
Neoadjuvant Therapy ◽  
Tumor Hypoxia ◽  
Pathological Response ◽  
Emission Tomography ◽  
Tumor Proliferation ◽  
Dce Mri ◽  
Positron Emission ◽  
Pet Ct

10512 Background: To investigate the role of DCE-MRI versus 18F-Misonidazole (FMISO) positron emission tomography (PET/CT) in the prediction of pathological response to bevacizumab-based neodajuvant therapy. Methods: 73 chemotherapy naïve, stage II and III breast cancer (BC) patients (pts) were enrolled in a phase II, single-arm, multicenter, open-label and prospective clinical trial. Pts received single infusion of bevacizumab (15 mg/ kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy (NAC) consisting of 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and bevacizumab (15 mg/ kg) every 21 days (C2-C5), followed by surgery. Tumor proliferation, hypoxia and perfusion were evaluated respectively using 18F-Fluorothymidine (FLT) and 18F-Misonidazole (FMISO) positron emission tomography (PET/CT) and dynamic contrast enhancement magnetic resonance (DCE-MR). Serial imaging studies were performed in parallel at several time points including baseline (BL) and 14-21 days after bevacizumab alone (C1). Results: After only one administration of bev, tumor proliferation and perfusion assessed using FLT-PET and DCE-MRI significantly decrease (-26% and -46%, p<0.001) but these changes were not found to be associated with final response. Most important, changes in tumor hypoxia induced by bevacizumab was significantly associated with pathological response (p= 0.004) and was an independent predictor of response in multivariate analysis (RR=0.95, IC 95% 0.92-0.99, p=0.02). Decrease in FMISO uptake >10% yielded a ROC curve area of 0.7 (95% CI: 0.56 - 0.85) with high specificity (94%). Conclusions: Our findings suggest a significant value of early changes in tumor hypoxia assessed by FMISO-PET as a biomarker of pathological response in bevacizumab-based neoadjuvant therapy in breast cancer.

18F-Fluorodeoxiglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal Cancer

2009 ◽  
Vol 250 (2) ◽  
pp. 247-254 ◽  
Author(s):  
Ángel C. Rebollo Aguirre ◽  
Carlos Ramos-Font ◽  
Román Villegas Portero ◽  
Gary J. R. Cook ◽  
José M. Llamas Elvira ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Therapy Response ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography

2001 ◽  
Vol 233 (3) ◽  
pp. 300-309 ◽  
Author(s):  
Björn L.D.M. Brücher ◽  
Wolfgang Weber ◽  
Markus Bauer ◽  
Ullrich Fink ◽  
Norbert Avril ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Therapy ◽  
Squamous Cell ◽  
Emission Tomography ◽  
Response Evaluation ◽  
Positron Emission

T1211 Early Response Assessment of Neoadjuvant Therapy With Positron Emission Tomography in Patients With Oesophageal Cancer

2010 ◽  
Vol 138 (5) ◽  
pp. S-512
Author(s):  
Mark van Heijl ◽  
Jikke M. Omloo ◽  
Mark I. van Berge Henegouwen ◽  
Otto S. Hoekstra ◽  
Ronald Boellaard ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Neoadjuvant Therapy ◽  
Oesophageal Cancer ◽  
Response Assessment ◽  
Early Response ◽  
Emission Tomography ◽  
Positron Emission ◽  
Early Response Assessment
Sign in / Sign up

Export Citation Format

Share Document